CHRM1 and diabetic neuropathy: This finding is consistent with a recent report of similar efficacy in subjects with diabetic neuropathy treated with the non-selective muscarinic antagonist oxybutynin28 and suggests M1R antagonism as the initial pharmacological approach to promote nerve regeneration in diabetic peripheral neuropathy.